<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; prices</title>
	<atom:link href="http://www.tapanray.in/tag/prices/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>When Patents, Patients and Prices Collide</title>
		<link>http://www.tapanray.in/when-patents-patients-and-prices-collide/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-patents-patients-and-prices-collide</link>
		<comments>http://www.tapanray.in/when-patents-patients-and-prices-collide/#comments</comments>
		<pubDate>Sun, 19 Oct 2025 12:39:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[atrophy]]></category>
		<category><![CDATA[Collide]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Evrysdi]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[muscular]]></category>
		<category><![CDATA[Natco Pharma]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Risdiplam]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[spinal]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10982</guid>
		<description><![CDATA[Supreme Court Clears Natco to Launch Low-Cost Version of Roche’s Spinal Drug in India: A Judgment That Redefines Access and Innovation in India’s Pharma Landscape. The Supreme Court of India has just recently refused to interfere with the Delhi High &#8230; <a href="http://www.tapanray.in/when-patents-patients-and-prices-collide/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-patents-patients-and-prices-collide/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Pricing: Why Justify On R&amp;D Cost Rather Than Precise ‘Customer Value’?</title>
		<link>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value</link>
		<comments>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/#comments</comments>
		<pubDate>Mon, 16 Dec 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[connects]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[electronics]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[justification]]></category>
		<category><![CDATA[justify]]></category>
		<category><![CDATA[lawsuit]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[monetary]]></category>
		<category><![CDATA[offerings]]></category>
		<category><![CDATA[Oregon]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9815</guid>
		<description><![CDATA[While looking around, it won’t be difficult to spot many types of steep-priced highly innovative products, where high costs aren’t justified by high R&#38;D expenditure, but for unique ‘customer value’ offerings. Many consumers evaluate those and decide to settle for &#8230; <a href="http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>On The Flip Side of Pharma Industry: A Saga of Perennial Contradictions</title>
		<link>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions</link>
		<comments>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/#comments</comments>
		<pubDate>Mon, 09 Dec 2019 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CEOs]]></category>
		<category><![CDATA[contradiction]]></category>
		<category><![CDATA[contradictions]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[flip]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[perennial]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[side]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vice versa]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9804</guid>
		<description><![CDATA[Awesome contribution in the battle against multiple diseases, is obviously the primary facet of the pharma industry. However, on its flip side, one would witness a saga of numerous contradictions. Some of these exist perennially in well-protected opaque cocoons, regardless &#8230; <a href="http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma’s Perception Management</title>
		<link>http://www.tapanray.in/pharmas-perception-management/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmas-perception-management</link>
		<comments>http://www.tapanray.in/pharmas-perception-management/#comments</comments>
		<pubDate>Mon, 23 Sep 2019 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[Bono]]></category>
		<category><![CDATA[designing]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expenses. expenditure]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[Gallup]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[input]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[output]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Policies]]></category>
		<category><![CDATA[Poll]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9721</guid>
		<description><![CDATA[An intriguing input-output relationship in the pharma industry has remained baffling, since the last several years, where increasing financial inputs are resulting in diminishing productivity output. More disturbing is, this input-output relationship has now reached a new low, with their &#8230; <a href="http://www.tapanray.in/pharmas-perception-management/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmas-perception-management/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Are Cancer Patients Victims of Pharma’s Payment to Doctors &#8211; For Prescriptions?</title>
		<link>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions</link>
		<comments>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/#comments</comments>
		<pubDate>Mon, 04 Mar 2019 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Evaluation]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pay]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Prescribing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[relatioship]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9432</guid>
		<description><![CDATA[In pharma industry, people of all socioeconomic backgrounds have no other choice but to visit doctors, to seek their expert advice for medical treatment. Patients expect them to prescribe the right and most affordable medicines for desired relief. Ironically, it &#8230; <a href="http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Creating ‘Shared Value’ in Pharma – The Way Forward</title>
		<link>http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=creating-shared-value-in-pharma-the-way-forward</link>
		<comments>http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/#comments</comments>
		<pubDate>Mon, 30 Jul 2018 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Arogya]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[CSR]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[forward]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Parivar]]></category>
		<category><![CDATA[philanthropy]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[shared]]></category>
		<category><![CDATA[social responsibility]]></category>
		<category><![CDATA[social. society]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[way]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9079</guid>
		<description><![CDATA[Many Pharmaceutical companies, both global and local, are struggling with a plethora of critical challenges. With the industry reputation diving south successful navigation through this headwind has become an onerous task, more than ever before. Under this backdrop, the article, &#8230; <a href="http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Healthcare in India And Hierarchy of Needs</title>
		<link>http://www.tapanray.in/healthcare-in-india-and-hierarchy-of-needs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=healthcare-in-india-and-hierarchy-of-needs</link>
		<comments>http://www.tapanray.in/healthcare-in-india-and-hierarchy-of-needs/#comments</comments>
		<pubDate>Sun, 05 Nov 2017 23:30:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[ease]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hierarchy]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[Hunger]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Maslow]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Obamacare]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[voters]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8545</guid>
		<description><![CDATA[“Russia and India climb World Bank’s Doing Business rankings”, was a headline in the Financial Times on October 31, 2017. India jumped 30 places &#8211; from 130 out of 190. Almost instantly, the domestic media flashed it all across the &#8230; <a href="http://www.tapanray.in/healthcare-in-india-and-hierarchy-of-needs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/healthcare-in-india-and-hierarchy-of-needs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dwindling Drug Innovation: Declining Image: Unchanged Business And Advocacy Models</title>
		<link>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models</link>
		<comments>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/#comments</comments>
		<pubDate>Mon, 20 Feb 2017 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chasing]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Dwinding]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rainbows]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8099</guid>
		<description><![CDATA[A report of ‘The United States International Trade Commission (USITC)’ released on December 22, 2014 suggested, if tariffs and investment restrictions were fully eliminated, and standards of IP protection were made comparable to the U.S and Western European levels, American &#8230; <a href="http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Cost-Effective Are New Cancer Drugs?</title>
		<link>http://www.tapanray.in/how-cost-effective-are-new-cancer-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-cost-effective-are-new-cancer-drugs</link>
		<comments>http://www.tapanray.in/how-cost-effective-are-new-cancer-drugs/#comments</comments>
		<pubDate>Mon, 30 Jan 2017 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[anticancer]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Buffet]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[effectiveness]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[malignant]]></category>
		<category><![CDATA[metastatic]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[prolong]]></category>
		<category><![CDATA[rate]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[survival]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[tumors]]></category>
		<category><![CDATA[Warren]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8061</guid>
		<description><![CDATA[The main reason why cancer is so serious a disease, is the ability of the malignant cells to spread in the body, both locally by moving into nearby normal tissue, and regionally to nearby lymph nodes, tissues, or organs, affecting even &#8230; <a href="http://www.tapanray.in/how-cost-effective-are-new-cancer-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-cost-effective-are-new-cancer-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alarming Incidence of Cancer: Fragile Infrastructure: Escalating Drug Prices</title>
		<link>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices</link>
		<comments>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/#comments</comments>
		<pubDate>Mon, 28 Jul 2014 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[alarming]]></category>
		<category><![CDATA[ASCO]]></category>
		<category><![CDATA[Astellas Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Celgene]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[escalating]]></category>
		<category><![CDATA[evaluate]]></category>
		<category><![CDATA[fact]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incidence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance Life Science]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sheet]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Zydus Cadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5672</guid>
		<description><![CDATA[According to the &#8216;Fact-Sheet 2014&#8242; of the World Health Organization (WHO), cancer cases would rise from 14 million in 2012 to 22 million within the next two decades. It is, therefore, no wonder that cancers figured among the leading causes &#8230; <a href="http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
